AZ takes 50% cut of Amylin diabetes portfolio through partnership with BMS
In a transaction that expands their diabetes partnership, Bristol-Myers Squibb Co. is granting AstraZeneca PLC a 50% share of the assets that BMS gains once it completes its concurrently announced $6.8bn acquisition of Amylin Pharmaceuticals Inc.
- Controlled Release
- Drug Delivery
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.